Financial Ratios

MANKIND PHARMA LTD.

NSE : MANKINDBSE : 543904ISIN CODE : INE634S01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE2368.25-26.4 (-1.1 %)
PREV CLOSE ( ) 2394.65
OPEN PRICE ( ) 2418.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10419
TODAY'S LOW / HIGH ( )2360.00 2450.00
52 WK LOW / HIGH ( )1240.75 2488.65
NSE2369.00-29.55 (-1.23 %)
PREV CLOSE( ) 2398.55
OPEN PRICE ( ) 2398.55
BID PRICE (QTY) 2369.00 (32)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 197510
TODAY'S LOW / HIGH( ) 2360.00 2452.45
52 WK LOW / HIGH ( )1242 2490
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)31.1634.6827.0723.9212.83
   CEPS(Rs)37.8937.7629.0225.4613.79
   DPS(Rs)0.000.000.003.104.45
   Book NAV/Share(Rs)194.31163.27118.1891.1576.51
   Tax Rate(%)20.1325.7624.7124.2525.64
Margin Ratios
   Core EBITDA Margin(%)20.0423.6223.9624.9817.74
   EBIT Margin(%)18.7824.6625.2925.6218.39
   Pre Tax Margin(%)18.4524.0525.1525.4017.39
   PAT Margin (%)14.7317.8518.9419.2412.93
   Cash Profit Margin (%)17.9219.4420.3020.4813.90
Performance Ratios
   ROA(%)13.6318.7720.9022.9213.08
   ROE(%)17.4324.6525.8628.5316.96
   ROCE(%)21.2031.8434.1636.9522.11
   Asset Turnover(x)0.931.051.101.191.01
   Sales/Fixed Asset(x)2.403.454.914.995.36
   Working Capital/Sales(x)4.045.052.854.416.07
Efficiency Ratios
   Fixed Capital/Sales(x)0.420.290.200.200.19
   Receivable days20.7519.6925.1120.4417.53
   Inventory Days49.5249.1043.3537.1943.64
   Payable days110.55109.68110.73101.44110.01
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)0.000.000.000.000.00
   Price/Book(x)0.000.000.000.000.00
   Yield(%)
   EV/Net Sales(x)-0.010.08-0.06-0.030.04
   EV/Core EBITDA(x)-0.060.29-0.22-0.120.20
   EV/EBIT(x)-0.070.30-0.24-0.120.22
   EV/CE(x)-0.010.07-0.06-0.040.04
   M Cap / Sales0.000.000.000.000.00
Growth Ratio
   Net Sales Growth(%)8.5635.5415.2025.21-2.27
   Core EBITDA Growth(%)-8.8933.7814.1273.90-21.46
   EBIT Growth(%)-17.0932.4913.5174.58-23.21
   PAT Growth(%)-10.1628.1313.1686.41-25.09
   EPS Growth(%)-10.1628.1313.1686.41-25.09
Financial Stability Ratios
   Total Debt/Equity(x)0.000.100.020.000.06
   Current Ratio(x)2.481.682.862.391.90
   Quick Ratio(x)1.751.132.171.731.24
   Interest Cover(x)56.3640.37175.93114.9418.45
   Total Debt/Mcap(x)

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.